NCT05614063Phase 3Completed

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Study sponsor: Xenon Pharmaceuticals Inc. · XENE

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-01-12Actual

Enrollment · participants380Actual

Source updated2026-05-14Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-13 · 5 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~360 participants (planned)~~

+ After

380 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Dec 2025~~

+ After

12 Jan 2026

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source